Investing.com··Timothy FriesGilead to Acquire Arcellx for $7.8B, Expanding CAR-T Therapy Portfolio
Gilead acquires Arcellx for $7.8B to expand CAR-T therapy portfolio, strengthening oncology pipeline and cell therapy capabilities.
GILDACLXacquisitionFDA approval